ExelixisEXEL
EXEL
About: Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Employees: 1,310
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 12 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
102% more first-time investments, than exits
New positions opened: 83 | Existing positions closed: 41
15% more capital invested
Capital invested by funds: $5.64B [Q2] → $6.48B (+$845M) [Q3]
9% more funds holding
Funds holding: 408 [Q2] → 445 (+37) [Q3]
1.43% more ownership
Funds ownership: 86.17% [Q2] → 87.6% (+1.43%) [Q3]
4% more call options, than puts
Call options by funds: $70.4M | Put options by funds: $67.6M
0% more funds holding in top 10
Funds holding in top 10: 7 [Q2] → 7 (+0) [Q3]
13% less repeat investments, than reductions
Existing positions increased: 140 | Existing positions reduced: 160
Research analyst outlook
12 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$29
20%
downside
Avg. target
$38
5%
upside
High target
$42
16%
upside
12 analyst ratings
9 positive
75%
3 neutral
25%
0 negative
0%
Oppenheimer Jay Olson 20% 1-year accuracy 21 / 104 met price target | 13%upside $41 | Outperform Maintained | 16 Jan 2025 |
Truist Securities Asthika Goonewardene 19% 1-year accuracy 5 / 27 met price target | 16%upside $42 | Buy Maintained | 15 Jan 2025 |
JMP Securities Silvan Tuerkcan 30% 1-year accuracy 17 / 56 met price target | 13%upside $41 | Market Outperform Maintained | 15 Jan 2025 |
Piper Sandler Joseph Catanzaro 27% 1-year accuracy 9 / 33 met price target | 2%upside $37 | Overweight Maintained | 13 Jan 2025 |
HC Wainwright & Co. Robert Burns 24% 1-year accuracy 38 / 160 met price target | 11%upside $40 | Buy Maintained | 10 Jan 2025 |
Financial journalist opinion
Based on 12 articles about EXEL published over the past 30 days
Positive
Zacks Investment Research
6 days ago
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Positive
Zacks Investment Research
6 days ago
5 Biotech Stocks Worth Adding to Your Portfolio in 2025
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid pipeline progress position INCY, BMRN, EXEL, HALO and BPMC well in this volatile sector.
Neutral
Zacks Investment Research
1 week ago
Exelixis Provides Preliminary 2024 Results and Outlook for 2025
EXEL reports preliminary 2024 revenues. The company also provides guidance for 2025 and other pipeline updates.
Positive
Zacks Investment Research
1 week ago
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Neutral
Business Wire
1 week ago
Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fiscal year 2024, provided financial guidance for fiscal year 2025 and delivered an update on its business. Exelixis anticipates 2025 will be a year of clinical and regulatory execution and continued growth for its cabozantinib franchise, as well as multiple data readouts for zanzalintinib and across its diversified pipeline of small molecules and biotherapeutics w.
Neutral
Seeking Alpha
1 week ago
The Best Defensive Stocks To Hedge Against Market Uncertainty
2025 has kicked off with an air of uncertainty as investors wait to see how Donald Trump's economic agenda will impact inflation. A potential bear market presents opportunities to reassess portfolios and focus on companies with strong fundamentals and growth potential. Seeking Alpha's Quant system emphasizes the importance of data-driven models over emotional reactions to volatile markets.
Positive
Zacks Investment Research
1 week ago
FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib
EXEL's sNDA seeking approval of cabozantinib for the treatment of pancreatic neuroendocrine tumors will not be discussed at an ODAC.
Positive
Seeking Alpha
1 week ago
Exelixis: Bullish On Cabo, Not So Convinced By It's Long-Term Replacement, Zanza
Exelixis' stock has surged over 45% since my "Sell" rating given in March last year, driven by strong performance of cabozantinib, which remains a leading TKI for various cancers. Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate zanzalintinib showing potential to offset future revenue losses. Exelixis is optimistic about new approvals for cabozantinib in neuroendocrine tumors and has promising pipeline assets besides zanzalintinib in various cancer indications.
Neutral
Business Wire
1 week ago
Exelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX®) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced it has been notified by the U.S. Food and Drug Administration (FDA) that the supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX®) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic (epNET) will no longer be the subject of discussion at an Oncologic Drugs Advisory Committee meeting. The sNDA remains under consideration b.
Neutral
Business Wire
2 weeks ago
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 5:15 p.m. PT / 8:15 p.m. PT. To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. Replays will also be available at the same location.
Charts implemented using Lightweight Charts™